Education
About Us
Working with TipRanks
Follow Us
Structure Therapeutics, Inc. Sponsored ADR (GPCR)
NASDAQ:GPCR
GPCR Stock Chart & Stats
$74.92
-$0.32(-1.18%)
At close: 4:00 PM EST
$74.92
-$0.32(-1.18%)
Day’s Range― - ―
52-Week Range$13.22 - $94.90
Previous CloseN/A
Volume219.80K
Average Volume (3M)1.08M
Market Cap
$4.55B
Enterprise Value$4.45B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Mar 26, 2026EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding70,639,190
10 Day Avg. Volume970,606
30 Day Avg. Volume1,081,913
Financial Highlights & Ratios
PEG Ratio3.15
Price to Book (P/B)1.65
Price to Sales (P/S)0.00
P/FCF Ratio-12.11
Enterprise Value/Market Cap0.98
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$106.50Price Target Upside42.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)-1.38
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy Of AleniglipronPhase 2b data showing roughly fifteen percent placebo‑adjusted weight loss at the highest dose combined with a competitive tolerability profile supports aleniglipron as a potential best‑in‑class oral GLP‑1 and bolsters commercial and M&A interest.
Partnerships And Intellectual PropertyA non‑exclusive freedom‑to‑operate license with Genentech/Roche and an associated upfront payment validates Structure Therapeutics' patent position and increases the likelihood of additional licensing revenue and strategic collaborations.
Pipeline Diversification With Amylin AssetA first‑in‑human oral amylin candidate provides a differentiated mechanism that could be combined with GLP‑1 assets to enhance therapeutic value and attract partners or acquirers.
Bears Say
Competitive LandscapeA crowded obesity drug field with numerous international small‑molecule entrants could limit differentiation, compress pricing power, and make it harder to capture substantial market share.
Safety And Tolerability ConcernsA higher incidence of vomiting reported in the Phase IIb aleniglipron program versus a competing oral candidate raises tolerability questions that could complicate regulatory review and slow commercial adoption.
Structure Therapeutics, Inc. Sponsored ADR News
GPCR FAQ
What was Structure Therapeutics, Inc. Sponsored ADR’s price range in the past 12 months?
Structure Therapeutics, Inc. Sponsored ADR lowest stock price was $13.22 and its highest was $94.90 in the past 12 months.
What is Structure Therapeutics, Inc. Sponsored ADR’s market cap?
Structure Therapeutics, Inc. Sponsored ADR’s market cap is $4.55B.
When is Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date?
Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date is Mar 26, 2026 which is in 43 days.
How were Structure Therapeutics, Inc. Sponsored ADR’s earnings last quarter?
Structure Therapeutics, Inc. Sponsored ADR released its earnings results on Nov 06, 2025. The company reported -$0.37 earnings per share for the quarter, the consensus estimate of -$0.37 by $0.
Is Structure Therapeutics, Inc. Sponsored ADR overvalued?
According to Wall Street analysts Structure Therapeutics, Inc. Sponsored ADR’s price is currently Undervalued.
Does Structure Therapeutics, Inc. Sponsored ADR pay dividends?
Structure Therapeutics, Inc. Sponsored ADR does not currently pay dividends.
What is Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate?
Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate is -0.37.
How many shares outstanding does Structure Therapeutics, Inc. Sponsored ADR have?
Structure Therapeutics, Inc. Sponsored ADR has 70,639,190 shares outstanding.
What happened to Structure Therapeutics, Inc. Sponsored ADR’s price movement after its last earnings report?
Structure Therapeutics, Inc. Sponsored ADR reported an EPS of -$0.37 in its last earnings report, expectations of -$0.37. Following the earnings report the stock price went down -1.882%.
Which hedge fund is a major shareholder of Structure Therapeutics, Inc. Sponsored ADR?
Currently, no hedge funds are holding shares in GPCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Structure Therapeutics, Inc. Sponsored ADR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$106.50 (42.15% Upside)
$106.50 (42.15% Upside)
Blogger Sentiment
Bullish
GPCR Sentiment 75%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 814.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 3.2%
Last 30 Days ▲ 3.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
149.56%
12-Months-Change
Fundamentals
Return on Equity
-25.31%
Trailing 12-Months
Asset Growth
-10.83%
Trailing 12-Months
Company Description
Structure Therapeutics, Inc. Sponsored ADR
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.
GPCR Stock 12 Month Forecast
Average Price Target
$106.50
▲(42.15% Upside)
Technical Analysis
Ownership Overview
9.55% Insiders
17.91% Mutual Funds
0.06% Other Institutional Investors
69.00% Public Companies and Individual Investors